He has been a vital part of Umeå Biotech Incubator (UBI) since its inception in 2003. But now, after 42 years of service in the biotech industry, it is time for respected research engineer Assar Bäckman to retire. “My work has been hugely varied, and over the years I have learned a great deal. I usually have an emergency solution to most things if needed”, says Assar.
Umeå-based biopharmaceutical company Omnio AB, which is currently awaiting efficacy data from preclinical wound studies using recombinant plasminogen, has recently appointed an internationally experienced board of directors charged with taking the company forward.
The Umeå-based biopharmaceutical company Omnio AB, focusing on wound healing, has received a capital injection of 1.5 million euros from its shareholders, which will be used for ongoing development work and to begin creating a blueprint for manufacturing.
Omnio AB is developing new drug products based on the pro-inflammatory and immune regulatory effects of the serum protein plasminogen. During fall the company successfully raised 5.5 MSEK in a new share issue and welcomed four new investors to the company. The added investments make it possible for the company to now initiate its planned activities to develop recombinant plasminogen for treatment
Omnio is primarily developing new treatment methods for chronic wounds. These methods are based on research conducted by Professor Tor Ny's group at Umeå University. Ulrika Norin, who recently took up her new position as CEO of Omnio in Marcha while back, has previously worked with various startups in the field of immuno-oncology, where she managed several development projects.